Human EGFR Gene T790M Mutation Detection Kit
Digital PCR assay
CE-IVD Certificate no.：No.MDD-SZ-XWA1-180523
Only for scientific research use in China
According to the detection of EGFR status for patients with NSCLC, exon 19 deletions mutations are found in 45% of the patients, and a mutation of exon 21 L858R is about 40%- 45%, while the mutations of exon 20 insertions occupies about 5%. The first and second generations of EGFR-TKI drugs are effective for patients harboured EGFR mutation menttioned above. Studies have shown that most EGFR-mutant NSCLC patients have a good response to EGFR-TKI initially. However, approximately 50-65% of the patients will have drug resistance caused by T790M mutation of EGFR after they have been treated with EGFR-TKI drugs for about 10 months.
Mechanismsof acquired resistance to first- and second-generation EGFR tyrosine kinaseinhibitors
WestoverD et al. Ann Oncol.2018 Jan 1;29(suppl_1):i10-i19. doi: 10.1093
|Product Name||Detecting Item||Technology||Product Specification||Sample Type||Matched Instrument|
Human EGFR Gene
|EGFR-T790M||Digital PCR||10 tests/kit|
Life QuantStudio 3D
● Through the detection of EGFR-T790M , the patients with drug resistance can be predicted earlier than the progress of the disease can be identified by conventional radiology.
● The detection results of EGFR-T790M can be used to predict the efficacy of the first and second generations of EGFR-TKI drugs and guide the selection for suitable target treatments.
●The patients with drug resistance to the first /second generation of EGFR-TKI drugs.
● The advanced patients who will be treated with Ochitinib, a detection of EGFR-T790M status is recommended.
Easy operation: Only 5 working days from sample processing to reporting.
Accuracy and Reliability：This kit can quantitatively detect the mutation abundance of T790M. The results can help monitor the development of the disease and adjust the therapeutic treatments in time .
High Sensitivity:This kit can detect as low as 0.1% mutation.More opportunities of treatments for patients with drug resistance who can not be acquired secondary biopsy.
No internal reference needed:Avoid fake negative.